Breviblok

Breviblok: description, application and side effects

Breviblock is a beta1-blocker that is used to treat arterial hypertension, sinus, supraventricular tachycardia, as well as unstable angina and myocardial infarction. The drug is available in the form of a concentrate for the preparation of infusion solution and solution for injection.

Manufacturers of Breviblok are Gensia Automedics from the UK. The international name of the drug is Esmolol. The active substance is esmolol hydrochloride.

Indications for the use of Breviblok include the treatment of arterial hypertension, sinus, supraventricular tachycardia, supraventricular tachyarrhythmia, including atrial fibrillation and flutter, as well as unstable angina and myocardial infarction. The drug can also be used to treat thyrotoxic crisis and pheochromocytoma.

However, Breviblok also has contraindications. The drug should not be used for bradycardia (less than 45 beats/min), second and third degree atrioventricular block, arterial hypotension, cardiogenic shock, acute heart failure and bronchospastic syndrome. The safety of the drug in children and pregnant women has not been studied, so its use in such cases is not recommended. It is also not recommended to use Breviblok while breastfeeding.

Side effects may occur when using Breviblok, such as feeling tired, drowsiness, confusion, headache, vomiting and signs of peripheral ischemia. In rare cases, burning, induration or infiltration of the skin around the site of drug administration (with extravasation), thrombophlebitis, bradycardia, palpitations, bronchospasm, dyspnea, speech disorders, vision, chills, fever, urinary retention and constipation, agitation and dizziness may occur. If these symptoms appear, you should immediately stop administering Breviblok.

Breviblok may also interact with other drugs. When Breviblok is combined with morphine and warfarin, its concentration in the blood increases. When Breviblok is combined with succinylcholine, the duration of neuromuscular blockade increases by 1.5 times. Breviblok may increase the effect of class I antiarrhythmic drugs such as lidocaine, procainamide and quinidine. Concomitant use of Breviblok with monoamine oxidase inhibitors (MAOIs) may lead to an enhanced hypotensive effect and an increased risk of serious side effects.

Before starting treatment with Breviblok, you should always consult with your doctor and report all medications you are taking, including prescription, over-the-counter and herbal medications, as well as any chronic diseases or allergies you have.

In general, Breviblok is an effective and safe drug, but its use should only be carried out as prescribed by a doctor and in compliance with all recommendations and precautions.